'Typical patients' diaporamas de présentation

JoAnne M. LaRow, D.O. Psoriasis, Seb Derm, Pustular Psoriasis, etc.

1.93k views • 134 slides

PK/PD Modeling in Support of Drug Development

PK/PD Modeling in Support of Drug Development. Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research Laboratories, Inc. alan_hartford@merck.com. Outline. Introduction Purpose of PK/PD modeling The Model Modeling Procedure

1.92k views • 30 slides

FVIII PRODUCT USAGE IN CLINICAL SETTINGS

FVIII PRODUCT USAGE IN CLINICAL SETTINGS. TSEAC October 31, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER, FDA. Topics. Issue: What data should be used to estimate how much FVIII is used by typical patients? Need to know: Definition of typical patient Dosage

261 views • 16 slides